Evidence map›Paper›PMID 24220357›Full record

ArticleSexually transmitted diseases2013

Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials.

Ariane van der Straten, Helen Cheng, Barbara Mensch, Barbara Friedland, Lauren Katzen, Sarah Littlefield, Niall Buckley, Lilia Espinoza, Marla J Keller, Betsy C Herold and 1 more

Open access · greenAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Sexually transmitted diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Ariane van der StratenFrom the *Women's Global Health Imperative, RTI International, San Francisco, CA; †Center for AIDS Prevention Studies (CAPS) Department of Medicine, UCSF, San Francisco, CA; ‡The Population Council, New York, NY; §Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; and ¶Albert Einstein Cancer Center, Bronx, NY.
Helen Cheng
Barbara Mensch
Barbara Friedland
Lauren Katzen
Sarah Littlefield
Niall Buckley
Lilia Espinoza
Marla J Keller
Betsy C Herold
Mark H Einstein
Population Council · USAlbert Einstein College of Medicine · USMontefiore Medical Center · USRTI International · USSan Francisco AIDS Foundation · US

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Core-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3M
Immunology/Pathology CoreP30AI051519 · NIAID · YESHIVA UNIVERSITY · PI GOLDSTEIN, HARRIS · 2003 to 2013
$18.6M
Clinical and Translational Science Award (UL1)UL1TR000086 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SHAMOON, HARRY · 2012 to 2013
$5.5M
Expanded Phase II Trial of Carraguard for Prevention of HPV InfectionR01CA148966 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI EINSTEIN, MARK H. · 2010 to 2015
$3.2M
NCATS NIH HHS 8UL1 TR001073NCATS NIH HHS UL1 TR001073NCI NIH HHS CA-148966NCI NIH HHS R01 CA148966NIAID NIH HHS 5UM1AI068633NIAID NIH HHS AI-051519NIAID NIH HHS P30 AI051519NIAID NIH HHS UM1 AI068633
6 · The paper itself

Abstract

backgroundAccurate measurement of adherence to product use is an ongoing challenge in microbicide trials.

methodsWe compared adherence estimates using 2 applicator tests (a dye stain assay [DSA] and an ultraviolet light assay [UVA]), the Wisebag (an applicator container that electronically tracks container openings), and self-reported adherence (ability, frequency, and percent missed doses). Healthy, HIV-negative, nonpregnant US women aged 23 to 45 years received a Wisebag and 32 applicators filled with placebo gel were instructed to insert 1 applicator daily for 30 days, returned the Wisebag and all applicators, and completed an exit interview. Emptied applicators were tested by UVA and then DSA, and scored by 2 blinded readers. Positive and negative controls were randomly included in applicator batches.

resultsAmong 42 women enrolled, 39 completed the study. Both DSA and UVA yielded similar sensitivity (97% and 95%) and specificity (79% and 79%). Two participants had fully inoperable Wisebags, and 9 had partially inoperable Wisebags. The proportion of participants considered to have high adherence (≥80%) varied: 43% (Wisebag), 46% (UVA), 49% (DSA), and 62% to 82% (self-reports). For estimating high adherence, Wisebag had a sensitivity of 76% (95% confidence interval, 50%-93%) and a specificity of 85% (95% confidence interval, 62%-97%) compared with DSA. Although 28% of participants reported forgetting to open the Wisebag daily, 59% said that it helped them remember gel use.

conclusionsDye stain assay and UVA performed similarly. Compared with these tests, self-reports overestimated and Wisebag underestimated adherence. Although Wisebag may encourage gel use, the applicator tests currently seem more useful for measuring use in clinical trials.

Indexed as

Administration, IntravaginalPatient ComplianceAdultAnti-Infective AgentsColoring AgentsCost-Benefit AnalysisDrug Delivery SystemsEquipment DesignFemaleHumansPredictive Value of TestsReproducibility of ResultsSensitivity and SpecificityUnited StatesVaginal Creams, Foams, and JelliesAnti-Infective AgentsColoring AgentsVaginal Creams, Foams, and Jellies

Identifiers

PMID24220357
PMCPMC4130378
OpenAlexW2020392532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.